Presentation from Metrion Biosciences’ external speaker series, Professor Nikita Gamper, University of Leeds, 5th February 2019.
Marc Rogers, CSO Metrion Biosciences
Presentation by Marc Rogers, CSO Metrion Biosciences, Nanion technologies Exhibitor session, 2020 Biophysical Society meeting, San Diego USA.
Please contact us if you would like any further information regarding our suite of cardiac safety services.
CiPA is designed to address drug-induced cardiac arrythmia (TdP) and the acute effects of drug discovery compounds (minutes – hours) with a focus on plasmalemmal ion channels that underlie the cardiac action potential.
However, new and existing drugs can also cause structural cardiotoxicity, produced by a diverse set of chemical compounds and primary target mechanisms. These chronic effects can appear after days, weeks or months; and not all are reversible.
Classic examples include:
Safety pharmacology testing therefore needs a reliable & predictive assay for chronic cardiotoxicity.
Presentation from Metrion Biosciences’ external speaker series, Professor Nikita Gamper, University of Leeds, 5th February 2019.
This talk was presented by Dr Sarah Williams at the Axol Metrion Interactive Stem Cell Forum held in May 2018. This project received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 Research and Innovation Program.